Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Operating Expenses (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Operating Expenses for 11 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 51.13% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, down 7.18% year-over-year, with the annual reading at $16.4 million for FY2025, 7.18% down from the prior year.
  • Operating Expenses for Q4 2025 was $3.0 million at Marker Therapeutics, down from $3.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $11.0 million in Q4 2021, with the low at $3.0 million in Q4 2025.
  • Average Operating Expenses over 5 years is $6.0 million, with a median of $5.0 million recorded in 2025.
  • The sharpest move saw Operating Expenses soared 59.86% in 2021, then tumbled 65.49% in 2022.
  • Over 5 years, Operating Expenses stood at $11.0 million in 2021, then crashed by 65.49% to $3.8 million in 2022, then rose by 5.17% to $4.0 million in 2023, then surged by 53.05% to $6.1 million in 2024, then tumbled by 51.13% to $3.0 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $3.0 million, $3.4 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.